Dual HER2 Blockade versus a Single Agent in Trastuzumab-Containing Regimens for HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

<div>Overall survival of trastuzumab-containing dual anti-HER2 therapy, all studies. IV: inverse-variance method; random: random-effects model; Moreno-Aspitia1 2017: trastuzumab plus lapatinib group; Moreno-Aspitia2 2017: trastuzumab followed by lapatinib group.</div>

Journal of Oncology

fig2

Figure 2

Figure 2: Dual HER2 Blockade versus a Single Agent in Trastuzumab-Containing Regimens for HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials 

Figure 2 | Dual HER2 Blockade versus a Single Agent in Trastuzumab-Containing Regimens for HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials 